Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2014

01-05-2014 | Hepatobiliary Tumors

Serum Antibody Titers Against Hepatitis C Virus and Postoperative Intrahepatic Recurrence of Hepatocellular Carcinoma

Authors: Mamoru Uemura, MD, PhD, Yo Sasaki, MD, PhD, Terumasa Yamada, MD, PhD, Kunihito Gotoh, MD, PhD, Hidetoshi Eguchi, MD, PhD, Masahiko Yano, MD, PhD, Hiroaki Ohigashi, MD, PhD, Osamu Ishikawa, MD, PhD, Shingi Imaoka, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2014

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is the seventh most common cancer and the third leading cause of cancer deaths worldwide. Hepatitis C virus (HCV) infection is a major risk factor for HCC recurrence after curative resection. This study evaluated anti-HCV antibody (Ab) titer as a prognostic indicator of HCC recurrence after curative hepatic resection.

Methods

A total of 82 patients with HCC (anti-HCV Ab positive and hepatitis B surface antigen negative) who underwent curative hepatic resection were evaluated. Anti-HCV Ab titers were measured using a third-generation enzyme immunoassay, and patients were divided into high (n = 41) and low (n = 41) titer groups to compare their clinicopathological characteristics and disease-free survival. Univariate and multivariate analyses were conducted to identify risk factors for early or late recurrence.

Results

Multivariate analysis showed that anti-HCV Ab titer and vascular invasion were independent prognostic factors of disease-free survival [odds ratio (OR) 1.9, p = 0.03, and OR 1.8, p = 0.04, respectively]. Subgroup analysis identified only vascular invasion as an independent prognostic factor for early recurrences that were considered residual intrahepatic metastases. Subgroup analysis identified anti-HCV Ab titer and fibrosis grade as independent prognostic factors of late recurrences that were considered to be metachronous multicentric liver carcinogenesis (OR 4.8, p = 0.04, and OR 5.2, p = 0.03, respectively).

Discussion

Anti-HCV Ab titer is a predictive factor for HCC recurrence, especially the risk of late recurrence due to multicentric carcinogenesis. Prevention of liver carcinogenesis after hepatic resection for HCC might be appropriate for patients with high anti-HCV Ab titers.
Literature
1.
Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2010;24:899–919, viii.
2.
El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.PubMedCrossRef
3.
Sasaki Y, Yamada T, Tanaka H, et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B– or hepatitis C–related hepatocellular carcinoma. Ann Surg. 2006;244:771–80.PubMedCentralPubMedCrossRef
4.
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485–91.PubMedCentralPubMedCrossRef
5.
6.
Tang ZY, Ye SL, Liu YK, et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:187–96.PubMedCrossRef
7.
8.
Belghiti J, Panis Y, Farges O, et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991;214:114–7.PubMedCentralPubMedCrossRef
9.
Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174–81.PubMedCrossRef
10.
Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051–5.PubMedCrossRef
11.
Tung HD, Lu SN, Lee CM, et al. Antiviral treatment responses in patients with chronic hepatitis C virus infection evaluated by a third generation anti-hepatitis C virus assay. J Viral Hepat. 2002;9:304–8.PubMedCrossRef
12.
Hara M, Mori M, Hara T, et al. Risk of developing hepatocellular carcinoma according to the titer of antibody to hepatitis C virus. Hepatogastroenterology. 2001;48:498–501.PubMed
13.
Jwo SC, Chiu JH, Chau GY, et al. Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology. 1992;16:1367–71.PubMedCrossRef
14.
Sakon M, Umeshita K, Nagano H, et al. Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg. 2000;135:1456–9.PubMedCrossRef
15.
Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.PubMedCrossRef
16.
Makuuchi M. The general rules for the clinical and pathological study of primary liver cancer. 4th ed. Tokyo: Kanehara; 2000.
17.
Liver Cancer Study Group of Japan (LCSGJ). The general rules for the clinical and pathological study of primary liver cancer. 5th ed. Tokyo: Kanehara 2008.
18.
Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513–20.PubMedCrossRef
19.
Tounou S, Hino K. Clinical and pathological study of asymptomatic hepatitis C virus (HCV) carriers. Ann Intern Med. 1998;132:517–24.
20.
Shimada M, Hasegawa H, Gion T, et al. Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy. Hepatogastroenterology. 1999;46:2469–75.PubMed
21.
Schvarcz R, Ando Y, Sonnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol. 1995;23(Suppl 2):17–21.PubMed
22.
Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35:1002–9.PubMedCrossRef
23.
Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets. 2006;6:3–16.PubMedCrossRef
24.
Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem. 2004;279:17508–14.PubMedCrossRef
25.
Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517–24.PubMedCrossRef
26.
Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–54.PubMedCrossRef
Metadata
Title
Serum Antibody Titers Against Hepatitis C Virus and Postoperative Intrahepatic Recurrence of Hepatocellular Carcinoma
Authors
Mamoru Uemura, MD, PhD
Yo Sasaki, MD, PhD
Terumasa Yamada, MD, PhD
Kunihito Gotoh, MD, PhD
Hidetoshi Eguchi, MD, PhD
Masahiko Yano, MD, PhD
Hiroaki Ohigashi, MD, PhD
Osamu Ishikawa, MD, PhD
Shingi Imaoka, MD, PhD
Publication date
01-05-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 5/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3417-4

Other articles of this Issue 5/2014

Annals of Surgical Oncology 5/2014 Go to the issue

Bone and Soft Tissue Sarcomas

Thoracopleuropneumonectomy with Riblike Reconstruction for Recurrent Thoracic Sarcomas

Healthcare Policy and Outcomes

Big Data and Clinical Research in Oncology: The Good, the Bad, the Challenges, and the Opportunities

Pediatric Oncology

Can Smaller-Scale Comprehensive Cancer Centers Provide Outstanding Care in Abdominal and Thoracic Pediatric Solid Tumor Surgery? Results of a 14-Year Retrospective Single-Center Analysis

Reconstructive Oncology

A Systematic Review of Morbidity Associated with Autologous Breast Reconstruction Before and After Exposure to Radiotherapy: Are Current Practices Ideal?

Healthcare Policy and Outcomes

In Memoriam: Donald L. Morton, MD (1934–2014): An Icon in Surgical Oncology

Pancreatic Tumors

Neoadjuvant Chemotherapy for Localized Pancreatic Cancer: Too Little or Too Long?